Lack of β-amyloid production in M19 cells deficient in site 2 processing of the sterol regulatory element binding proteins  by Manni, Mara E et al.
Lack of L-amyloid production in M19 cells de¢cient in site 2 processing
of the sterol regulatory element binding proteins
Mara E. Manni, Renzo Cescato, Paolo A. Paganetti*
Novartis Pharma Ltd., S.386.8.28, P.O. Box, CH-4002 Basel, Switzerland
Received 9 April 1998
Abstract The processing of the amyloid precursor protein
(APP) and the sterol regulatory element binding protein show
remarkable analogies. Following a first lumenal cleavage, both
proteins undergo a cleavage within the transmembrane domain
by enzymatic activities named Q-secretase and S2P, respectively.
We analyzed the processing of APP in the mutant Chinese
hamster ovary (CHO) cell line M19 which lacks the S2P gene
encoding for a putative metalloprotease. In these cells, we were
not able to detect any L-amyloid production from endogenous or
transiently overexpressed APP, although the transport of APP
along the secretory pathway, its processing by K- and L-
secretase, as well as its secretion were normal. This strongly
suggests that the Q-secretase cleavage in M19 cells is severely
impaired.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
L-Amyloid (AL), a 39- to 43-amino acid peptide thought to
play a crucial role in the pathogenesis of Alzheimer’s disease,
is generated from the amyloid precursor protein (APP) [1,2].
In a process de¢ned as protein ectodomain shedding [3], two
enzymatic activities, L- and K-secretase, release APP from
membranes [4,5]. Although ubiquitous, these two activities
may vary their relative contribution to the secretion of APP
in di¡erent cells [6]. The L-secretase cleaves at the amino-
terminus of the AL sequence, yielding the soluble amyloid
precursor protein sAPPL and the membrane-bound C99.
The K-secretase cleaves within the AL sequence generating
sAPPK and C83. The two carboxy-terminal fragments C99
and C83 are either degraded or processed by the Q-secretase
to generate AL or the shorter peptide P3 [7]. The correct
sequence of proteolytic cuts is necessary for the production
of AL [8,9]. L- and K-secretase require a membrane-bound
substrate and thus cleave only APP with an intact transmem-
brane domain. On the other hand, Q-secretase does not cleave
full-length APP. AL peptides di¡er in length at their carboxy-
termini [10]. Longer AL forms are more prone to form ¢brils
and are preferentially deposited in plaques [11]. In hereditary
Alzheimer’s disease, mutations of codon 717 of the APP gene
or mutations along most of the sequence of the presenilin
genes, signi¢cantly increase the proportion of the longer AL
peptides [12,13]. Drugs inhibiting Q-secretase block AL gener-
ation [14]. When these studies were extended to include minor
AL species, it was found that with some inhibitors the reduc-
tion of AL40 was accompanied by an increase in AL42 [15,16].
In addition, AL40 and AL42 may be formed in di¡erent cel-
lular compartments [17]. It was therefore suggested that dis-
tinct Q-secretase activities generate AL40 and AL42.
It is remarkable that Q-secretase(s) cut(s) within the mem-
brane-spanning domain of APP. So far, only one other exam-
ple of a proteolytic cleavage in a transmembrane region was
reported, the processing of sterol regulatory element binding
proteins (SREBPs). SREBPs are membrane-bound transcrip-
tion factors regulating the expression of enzymes involved in
the cholesterol and fatty acid biosynthesis and the transcrip-
tion of the low density lipoprotein (LDL) receptor [18]. Two
sequential cleavages release the active transcription factor do-
main from the membrane of the endoplasmic reticulum. In
cholesterol-depleted cells, SREBP-2 is cleaved lumenally at
site 1 between the two transmembrane domains [19]. This
event is tightly regulated by a cholesterol-sensing protein
named SCAP [20]. The cleavage at site 2 occurs thereafter
in the ¢rst membrane-spanning domain of SREBP-2 by a
constitutively active protease [19]. A candidate site 2 protease
has been recently identi¢ed and named S2P [21]. S2P is a
putative metalloprotease with several predicted transmem-
brane domains, which would de¢ne a new class of proteases.
Despite the analogies in SREBPs and APP processing, some
notable di¡erences exist. First, site 2 is in a domain spanning
the membrane in the opposite orientation to that cleaved by
Q-secretase. Second, no metalloprotease inhibitors are known
to inhibit Q-secretase. Finally, S2P seems to be active in the
endoplasmic reticulum [19], whereas the cleavage of APP by
Q-secretase is thought to occur in a late compartment of the
secretory pathway or in an endocytic/lysosomal compartment
[1,2].
To investigate if APP and SREBPs are cleaved by the same
or similar enzymes, we analyzed APP processing in M19 cells
[22]. These mutant CHO cells lack the S2P gene and thus are
de¢cient in site 2 processing of SREBPs [20]. Our data suggest
that M19 cells lack Q-secretase activity, whereas the transport
of APP along the secretory pathway as monitored by post-
translational modi¢cations such as glycosylation, tyrosine sul-
fation, processing by K- and L-secretase, as well as its secre-
tion, are not altered compared to parental CHO cells.
2. Materials and methods
2.1. Materials
The cDNA constructs encoding APP695, APP carrying the Swedish
K595M596-NL mutation (APPswe) and APP truncated at position 40
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of the AL sequence (APP.40) were described previously [9,23].
SPENKC99 was obtained by cloning the C99 cDNA sequence down-
stream of the human preproenkephalin signal peptide after ampli¢ca-
tion by polymerase chain reaction. Recombinant protein expression
was driven by the cytomegalovirus promoter and by the SV40 poly-
adenylation signal contained in the vector [24].
The rabbit polyclonal antisera AS NT11, AS APPC, AS 40, AS 16
and the mouse monoclonal antibody L1 were raised as described
[9,23], the monoclonal antibody 6E10 was obtained from Senetek.
AS NT11 and AS 40 recognise the carboxy-termini of AL40 and
P3. L1 and 6E10 react with a human speci¢c epitope of AL40,
AL42, full-length APP and sAPPK. AS APPC recognises full-length
APP and the carboxy-terminal fragments C99 and C83. AS 16 recog-
nises speci¢cally the free carboxy-terminus of sAPPK.
2.2. Transient cell transfections
Chinese hamster ovary cells CHO-K1 (ATCC CCL61) and M19
cells [22] were grown in Dulbecco’s modi¢ed Eagle medium (Gibco-
BRL), 10% foetal bovine serum (Gibco-BRL), 40 mg/l proline (Sigma)
and 1% penicillin/streptomycin (Gibco-BRL) at 37‡C/5% CO2.
For transfection by electroporation, 5^10U106 CHO or M19 cells
were resuspended in 400 Wl culture medium. The cells were incubated
at room temperature for 5^10 min with 20 Wg relevant plasmid in a
0.4-cm gap cuvette (Bio-Rad). The electroporation was performed at
room temperature using a Bio-Rad Gene Pulser II set at 350 V and
450 WF. Transfected cells were then seeded in a 10-cm culture dish and
incubated for the indicated time.
For lipid-mediated transfection, 1.9U106 cells were seeded a day
earlier in a 10-cm culture dish. Transfection was performed with Fu-
Gene 6 (Boehringer Mannheim) following the instructions of the man-
ufacturer. In brief, 19 Wl FuGene 6 diluted in 600 Wl PBS were care-
fully mixed with 6 Wg relevant plasmid. Following a 15-min
incubation, the transfection mixture was added to 80% con£uent cells
in 12 ml culture medium.
2.3. Immunoprecipitations and immunoblots
Cell media and cell extracts were prepared and used for immuno-
precipitations as previously described [23]. Precipitated proteins were
resolved by sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and blotted to Immobilon P membranes (Millipore)
[23,25]. Membranes were blocked with 5% (w/v) low-fat milk powder
in phosphate bu¡ered saline, 0.05% Tween-20 (PBST), and incubated
overnight at 4‡C with ¢rst antibodies diluted in PBST. Bound anti-
bodies were detected with goat anti-rabbit IgG (Jackson Immuno-
Research Laboratories, Inc.) or goat anti-mouse IgG (Chemicon) con-
jugated to horseradish peroxidase diluted in PBST using the ECL
detection system (Amersham).
2.4. Metabolic labeling and sulfate labeling
For labeling with [35S]methionine/cysteine, CHO and M19 cells
were grown to subcon£uency in 10-cm culture dishes. Cells were
then pulse-labeled overnight and cell media immunoprecipitated as
described previously [23].
Labeling with [35S]sulfate was performed as described [26]. Brie£y,
CHO and M19 cells grown to subcon£uency in 10-cm culture dishes
were washed once and subsequently starved for 30 min at 37‡C/5%
CO2 with sulfate-free medium. Cells were pulse labeled with 1 mCi/ml
[35S]sulfate (NEN DuPont, Sulfur-35 as sodium sulfate) for 3.5 h at
37‡C/5% CO2. sAPPK was immunoprecipitated from cell media as
described above.
Radiolabeled proteins were analyzed as described previously [23].
3. Results
The processing of APP was analysed in M19 cells, a mutant
CHO cell line de¢cient in S2P processing of the SREBPs [22].
M19 cells grown in regular Dulbecco’s modi¢ed Eagle me-
dium containing 10% foetal bovine serum were transfected
by electroporation with a cDNA encoding human APP695.
Two days post-transfection, the cell medium was collected
and analysed by immunoprecipitation followed by immuno-
blotting using the two monoclonal antibodies against AL L1
and 6E10. Under these experimental conditions, neither AL40
nor AL42 were detected in the conditioned medium of trans-
fected M19 cells (Fig. 1A). However, when APP was trans-
fected into the parental CHO cells, a large amount of both AL
peptides was generated. Analysis of the cell lysates by immu-
noblotting with the antiserum AS APPC revealed that com-
parable levels of transgenic APP were expressed in both trans-
fected cell types (Fig. 1B). While a small amount of AL was
found in cell extracts of transfected CHO cells, no AL could
be detected in M19 cell extracts (Fig. 1C), indicating that lack
of AL peptides in the medium of these cells was not due to a
defect in protein secretion. This was further con¢rmed by
analysis of sAPPK, the soluble form of APP generated by
K-secretase, which was secreted as e⁄ciently by M19 as by
CHO cells (Fig. 1D). To monitor the formation of P3, a
metabolite of APP generated by K- and Q-secretase cleavage,
the cell media were also analysed using the two polyclonal
antibodies AS NT11 and AS 40 against the carboxy-terminal
region of AL. As found for AL peptides, M19 cells did not
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Fig. 1. Lack of AL- and P3-peptide production in M19 cells transi-
ently expressing human APP. Cell media and lysates from CHO or
M19 cells were collected 2 days post-transfection by electroporation
(A^E) or FuGene (F). Mock transfected cells were used as control.
Samples were immunoprecipitated with L1 (A,C,F), AS APPC (B),
AS 16 (D) or NT11 (E). Precipitated protein was separated by 10%
8 M urea (A,C) or 13.2% 17.4% glycerol (E,F) Tris/bicine SDS-
PAGE, or by 10% Tris/glycine SDS-PAGE (B,D). Immunoblots us-
ing 6E10 (A^D,F) or AS 40 (E) were developed with the ECL de-
tection system. Synthetic AL1-40 and AL1-42 were loaded onto the
gels as reference (A,B).
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secrete any detectable P3 like-peptides, while these were gen-
erated in CHO cells (Fig. 1E). Altogether, these data indicate
that M19 cells are de¢cient in APP processing to AL and P3,
whereas the expression, the transport along the secretory
pathway, the processing by K-secretase and the secretion of
APP are similar to the parental CHO cells. Alternatively to
electroporation, high levels of APP expression were also
achieved by lipid-mediated transfection of the APP cDNA
as found by immunoblot using AS APPC or L1 (not shown).
Again, we did not ¢nd evidence for AL generation in M19
cells, whereas AL secreted from CHO cells was detectable al-
ready in one tenth of the cell medium (Fig. 1F). To further
challenge the detection sensitivity of our method, cells were
transfected with the APPswe cDNA. As expected, this APP
mutant led to a ¢ve- to ten-fold increase in AL generation in
CHO cells (not shown). However, M19 cells expressing
APPswe did not secrete any detectable AL peptides (Fig. 2).
These ¢ndings, strongly supporting the notion that the pro-
duction of AL in M19 cells is severely impaired, were consis-
tently reproduced several times.
The generation of AL from transfected human APP was
analysed in hamster cells. To exclude the possibility of an
e¡ect both mediated by the transient transfection or speci¢c
for the human sequence in M19 cells, we also investigated the
processing of endogenous APP in metabolically labeled cells.
Following an overnight pulse, cell media were analysed by
immunoprecipitation and electrophoresis. Consistent to the
above conclusion, M19 cells completely lacked the capability
to generate AL- or P3-peptides (Fig. 3A), while soluble sAPPK
was formed by both M19 and CHO cells (Fig. 3B). When
APP was radiolabeled by sulfation, a post-translational mod-
i¢cation occurring in the trans-Golgi/TGN compartment,
again sAPPK was released by both mutant and parental
CHO cells (Fig. 3B). These data further support the view
that in M19 cells APP is e⁄ciently transported along the
secretory pathway and correctly post-translationally modi¢ed.
To monitor the generation of C99, the carboxy-terminal me-
tabolite of APP generated by L-secretase, cells were trans-
fected with APPswe. Cell extracts were then analysed by im-
munoprecipitation with a polyclonal antibody speci¢c for the
carboxy-terminus of APP. We observed that C99 was gener-
ated in M19 cells as e⁄ciently as in CHO cells (Fig. 4A). Since
L- and K-secretase processing of APP is normal, whereas fur-
ther processing to AL and P3 is de¢cient, we conclude that
M19 cells lack any detectable Q-secretase activity.
Finally, M19 cells were transfected with cDNA constructs
encoding arti¢cially truncated APP molecules. APP.40 is trun-
cated at the Q-secretase cleavage site and does not insert into
membranes, it is e⁄ciently secreted without any proteolytic
processing and, therefore, serves as a marker for secretion
[9]. The SPENKC99 construct drives the expression of the
L-secretase product C99 which only requires Q-secretase cleav-
age to generate AL [9]. Analysis of the cell media by immuno-
blot showed that soluble APP-like material corresponding to
APP.40 was secreted by both transfected M19 and CHO cells
(Fig. 4B). However, M19 cells did not release AL from C99
(Fig. 4C). In CHO cells, C99 is processed to AL as e⁄ciently
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Fig. 4. The Q-secretase activity, but not APP secretion, is severely
impaired in M19 cells. CHO or M19 cells were transfected with
APPswe (A), APP.40 (B) and SPENKC99 (C). Cell lysates were im-
munoprecipitated with AS APPC, run on a 10% Tris/bicine SDS-
PAGE and immunoblotted with 6E10. No di¡erence was observed
between CHO and M19 cells in the steady-state expression of full-
length APP (APPFL) and C99 (A). To better visualize APPFL, a
shorter exposure of the same immunoblot is shown at the top. Cell
media were immunoprecipitated with L1, run on a 8% or 13.2%
Tris/bicine SDS-PAGE and immunoblotted with 6E10 (B,C). Secre-
tion of APP.40 occurs to the same extent in CHO and M19 cells
(B), where the production of AL from C99 is severely impaired in
M19 cells (C).
Fig. 3. Lack of AL production from endogenous hamster APP in
M19 cells. Cells were pulsed overnight with [35S]methionine or for
3.5 h with [35S]sulfate. Cell media were immunoprecipitated with AS
NT11 (A) to detect AL and P3, or with AS 16 (B) to detect sAPPK.
Precipitated protein was resolved by 13.2% Tris/bicine (A) or 10%
Tris/glycine SDS-PAGE (B). Molecular weight markers are given on
the right of the autoradiogramms.
Fig. 2. Transiently expressed APPswe is not processed to AL in
M19 cells. Cell media from CHO or M19 cells were collected 2 days
after transfection, immunoprecipitated with L1, separated on a
13.2% Tris/bicine SDS-PAGE and immunoblotted with 6E10 (A).
To visualize AL, the same immunoblot was exposed for a longer
time (B). Total cell lysates were obtained in sample loading bu¡er.
The samples were then separated on a 8% Tris/bicine SDS-PAGE
and immunoblotted with 6E10 (C).
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as APPswe. These data further support the hypothesis that the
processing of APP in CHO and M19 cells is generally similar,
but that M19 cells lack any Q-secretase activity.
4. Discussion
The processing of endogenous hamster APP and transiently
expressed human APP was analyzed in M19 cells. In these
cells, we were not able to detect any Q-secretase activity, i.e.
the cleavage of the carboxy-terminal fragments C99 and C83
resulting in the generation of AL and P3, respectively. In
contrast, APP expression, the transport of APP along the
secretory pathway, post-translational modi¢cations such as
glycosylation (not shown) and tyrosine sulfation, APP proc-
essing by K- and L-secretase as well as its secretion, occurred
as e⁄ciently as in parental CHO cells.
M19 cells lack the gene for S2P, a putative metalloprotease
that is responsible for the cleavage at site 2 within the trans-
membrane domain of SREBPs [21]. The data presented here
suggest that in CHO cells S2P may also have Q-secretase ac-
tivity. If S2P is indeed the Q-secretase, the enzyme would have
the ability to cleave transmembrane domains of both type I
and type II orientations. Furthermore, this would mean that
Q-secretase belongs to the family of metalloproteases, although
no inhibitors of this class of enzymes have been reported to
inhibit AL generation. On the other hand, S2P could have an
indirect e¡ect on AL generation by activating the Q-secretase,
as known for other proteolytic cascades. However, this ap-
pears to be unlikely, since metalloprotease inhibitors should
again be active. An alternative possibility is that S2P may be
involved in the intracellular transport of APP or Q-secretase,
thus in S2P de¢cient cells the two partners would not come in
contact and APP processing would be impaired. Our data
suggest that dramatic alterations in the vectorial transport
of APP can be excluded (see above). Finally, due to the S2P
deletion, M19 cells are not able to upregulate the expression
of several enzymes involved in the synthesis of cholesterol and
fatty acids as well as the synthesis of the LDL receptor [22].
This defect could lead to a dramatic change in the physico-
chemical properties of membranes and therefore indirectly
a¡ect Q-secretase activity and thus AL generation. In prelimi-
nary experiments, transient overexpression of S2P in M19
cells did not restore AL generation (not shown), supporting
the idea of an indirect e¡ect of S2P on Q-secretase processing.
This possibility appears attractive in view of the fact that
ApoE4, a cholesterol transporting protein, is a risk factor of
AD. Interestingly, APP overexpressing transgenic mice lack-
ing the ApoE gene do not form plaques [26].
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